

**Adult CIRB – Early Phase Emphasis  
Meeting Agenda**

**Tuesday, November 7, 2017**

---

**I Amendment Review**

**9922**, A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance (Protocol Version Date 09/25/17)

---

**II Amendment Review**

**9974**, A phase II study of olaparib plus cediranib in combination with standard therapy for small cell lung cancer (Protocol Version Date 10/03/17)

---

**III Amendment Review**

**9924**, A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL) (Protocol Version Date 09/18/17)

---

**IV Continuing Review**

**9782**, A Phase 1 Study of BMN 673 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors (Protocol Version Date 09/20/17)

---